Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €54.28 EUR
Change Today -0.47 / -0.86%
Volume 3.9K
GENP On Other Exchanges
Symbol
Exchange
EN Paris
Berlin
OTC US
As of 11:35 AM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

stallergenes (GENP) Snapshot

Open
€54.88
Previous Close
€54.75
Day High
€54.88
Day Low
€53.02
52 Week High
02/27/15 - €59.39
52 Week Low
12/8/14 - €46.60
Market Cap
752.2M
Average Volume 10 Days
4.2K
EPS TTM
€3.13
Shares Outstanding
13.9M
EX-Date
07/3/15
P/E TM
17.3x
Dividend
€0.75
Dividend Yield
1.38%
Current Stock Chart for STALLERGENES (GENP)

Related News

No related news articles were found.

stallergenes (GENP) Related Businessweek News

No Related Businessweek News Found

stallergenes (GENP) Details

Stallergenes SA, a biopharmaceutical laboratory, engages in the research, development, manufacture, and marketing of allergen immunotherapy medicines in France and internationally. The company offers sublingual products, such as Staloral and Oralair containing allergen extracts; and subcutaneous products, including Alustal and Phostal injectable suspensions containing allergen extracts, as well as Albey and Alyostal hymenoptera venoms. It also provides other diagnostic products, such as Alyostal Pricks, a Glycero-saline solution for IR-IC/ml prick test; Alyostal intra-dermal-reaction powder and solvent for intra-dermal-test solution; Alyostal nasal provocation test powder and solvents; Alyostal conjunctival provocation test powder and diluents; Trolab, a pre-filled syringes for cutaneous applications; and True Test, a transdermal device to aid diagnosis of allergens that cause contact dermatitis. In addition, the company offers medical devices comprising Stallerpoint and Pricks lancet devices for prick tests; and NIOX MINO device to evaluate allergic airway inflammation in patients with underlying asthma. It offers its products in injectable, liquid sublingual, and solid sublingual forms in approximately 23 countries. The company has partnership agreement with DBV Technologies, ActoGeniX, Shionogi & Co. Ltd, and Greer Laboratories Inc. Stallergenes SA was founded in 1962 and is headquartered in Antony, France.

1,040 Employees
Last Reported Date: 04/29/15
Founded in 1962

stallergenes (GENP) Top Compensated Officers

Chief Executive Officer, Director, Member of ...
Total Annual Compensation: €592.0K
Deputy Chief Executive Officer and Chief Phar...
Total Annual Compensation: €37.0K
Compensation as of Fiscal Year 2014.

stallergenes (GENP) Key Developments

Stallergenes S.A. Presents at French Life Science Days conference, Jun-17-2015

Stallergenes S.A. Presents at French Life Science Days conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.

Stallergenes S.A. Reports Sales Results for the First Quarter of 2015

Stallergenes S.A. reported sales results for the first quarter of 2015. For the quarter, the company's net sales were EUR 81.3 million compared to EUR 75.7 million a year ago.

Stallergenes S.A. Announces Consolidated Earnings Results for the Year Ended December 2014; Provides Earnings Guidance for 2015

Stallergenes S.A. announced consolidated earnings results for the year ended December 2014. For the period, the company reported net sales of EUR 250.5 million compared to EUR 244.5 million a year ago. Total revenues were EUR 251.3 million compared to EUR 248.1 million a yea ago. Current operating profit was EUR 64.5 million compared to EUR 62.5 million a year ago. Operating profit was EUR 60 million compared to EUR 58.1 million a yea ago. Net profit was EUR 43.3 million compared to EUR 40.4 million a year ago. EBITDA was EUR 75.6 million compared to EUR 71.3 million a year ago. In 2015, the company targets a growth rate in net sales comparable to 2014, and stable EBITDA in comparison with 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GENP:FP €54.28 EUR -0.47

GENP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ALK-Abello A/S kr789.00 DKK +9.00
Allergy Therapeutics PLC 23.50 GBp +1.63
DBV Technologies SA €55.76 EUR +3.89
Merck & Co Inc $57.63 USD +0.70
Sanofi €89.70 EUR +1.46
View Industry Companies
 

Industry Analysis

GENP

Industry Average

Valuation GENP Industry Range
Price/Earnings 16.2x
Price/Sales 2.8x
Price/Book 2.5x
Price/Cash Flow 16.1x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STALLERGENES, please visit www.stallergenes.fr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.